

Tumormarker-Diagnostik im Urin

Prof. Dr. med. Stefan Holdenrieder

Referenzen

1. Schweizerische Eidgenossenschaft; Bundesamt für Statistik.
<https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/krankheiten/krebs.html> Stand 12.11.2020
2. Stieber P, Heinemann V. Sinnvoller Einsatz von Tumormarkern. J Lab Med 2008; 32: 339-360.
3. Holdenrieder S. Trends im Einsatz von Tumormarkern im klinischen Alltag.
MedWelt 2013/1: 12-19.
4. Trapé J, Filella X, Alsina-Donadeu M, et al. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011; 49: 1605- 1620.
5. Holdenrieder S. in Gressner A: Lexikon der Labormedizin, Springer-Verlag, 3. Auflage, 2019: Kochprobe und Leichtketten.
6. Auprich M, Bjartell A, Chun FKH, et al. Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. Eur Urol 2011; 60: 1045-54.
7. Perdonà S, Cavadas V, Di Lorenzo G, et al. Prostate cancer detection in the „grey area“ of prostate-specific antigen below 10 ng/mL: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011; 59: 81–87
8. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001; 92: 2820–2828.
9. Silen A, Rizvi SS, Letocha H et al. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer. Oncol Rep 2000; 7:1269–1274.
10. Jeong S, Park Y, Cho Y, et al. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta 2012; 414: 93-100.

11. Sturgeon CM, Duffy MJ, Hofmann BR et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. *Clin Chem* 2010; 56: e1–48.
12. Mahnert B, Tauber S, Kriegmair M, et al. Measurements of complement factor H-related protein (BTA-TRAK Assay) and nuclear matrix protein (NMP22 Assay) – useful diagnostic tools in the diagnosis of urinary bladder cancer? *Clin Chem Lab Med* 2003; 41:104–110.
13. Hasholzner U, Stieber P, Zimmermann A et al. Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases. *Anticancer Res* 1999; 19:2415–2420
14. Chou R, Gore JL, Buckley D, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Metaanalysis. *Ann Intern Med* 2015; 163: 922-31
15. Smith CG, Moser T, Moulriere F, et al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. *Genome Medicine* 2020; 12: 23.
16. Dinges, S, Hohm A, Vandergrift LA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Doi 10.1038/s41585-019-0185-3